|
Match
|
Document |
Document Title |
|
|
US20070218138 |
Pharmaceutical Compositions
Forms and formulations of VX-950 and uses thereof. |
|
|
US20160244497 |
FGF21 MUTANTS AND USES THEREOF
The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for... |
|
|
US20160199435 |
METHODS FOR PREVENTING OR TREATING METABOLIC SYNDROME
The invention provides methods of preventing or treating metabolic syndrome in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic... |
|
|
US20150231204 |
PANCREATIC POLYPEPTIDE FAMILY MOTIFS, POLYPEPTIDES AND METHODS COMPRISING THE SAME
The present invention provides novel Pancreatic Polypeptide Family (“PPF”) polypeptides and methods for their use. |
|
|
US20140296139 |
MITOCHONDRIAL-DERIVED PEPTIDE MOTS3 REGULATES METABOLISM AND CELL SURVIVAL
MOTS3 is a novel polypeptide. Methods of treating diseases such as diabetes, obesity, fatty liver, and cancer using MOTS3 and pharmaceutical compositions thereof are disclosed herein. |
|
|
US20120083442 |
MYOSTATIN BINDING AGENTS
The present invention provides binding agents comprising peptides capable of binding myostatin and inhibiting its activity. In one embodiment the binding agent comprises at least one... |
|
|
US20110039766 |
METHODS FOR PREVENTING OR TREATING METABOLIC SYNDROME
The invention provides methods of preventing or treating metabolic syndrome in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic... |
|
|
US20100136105 |
PHARMACEUTICAL COMPOSITIONS AND DOSAGE FORMS FOR ADMINISTRATION OF HYDROPHOBIC DRUGS
The present invention relates to pharmaceutical compositions and methods for improved solubilization of triglycerides and improved delivery of therapeutic agents. Compositions of the present... |
|
|
US20100113363 |
Use of GLP-1 Peptides
GLP-1(1-45) or a fragment or an analogue thereof can be used in the preparation of a medicament for peripheral administration in the suppression of appetite or induction of satiety. |
|
|
US20090170778 |
PYY Agonists and Uses Thereof
The invention provides PYY3-36 variants and pegylated derivatives thereof and compositions and methods useful in the treatment of conditions modulated by an NPY Y2 receptor agonist. |
|
|
US20090149387 |
Use of GLP-1 Peptides
GLP-1(1-45) or a fragment or an analogue thereof can be used in the preparation of a medicament for peripheral administration in the suppression of appetite or induction of satiety. |
|
|
US20080102124 |
Modified Human Growth Hormone
Modified growth hormone polypeptide and uses thereof are provided. |
|
|
US20070027085 |
Microencapsulation and sustained release of biologically active polypeptides
This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically... |
|
|
US20050143303 |
Intranasal administration of glucose-regulating peptides
Pharmaceutical compositions and methods are described comprising at least one glucose-regulating peptide, such as amylin, glucagon-like peptide-1 (GLP), pramlintide or exendin-4 and one or more... |
|
|
US20160228503 |
Compositions and Formulations for Prevention and Treatment of Diabetes and Obesity, and Methods of Production and Use Thereof in Glucose and Caloric Control
Nutritive polypeptides are provided herein. Also provided are various other embodiments including nucleic acids encoding the polypeptides, recombinant microorganisms that make the polypeptides,... |
|
|
US20150274634 |
COMPOUNDS FOR THE TREATMENT OF OBESITY AND METHODS OF USE THEREOF
Pentacyclic triterpene compounds are provided herein. Also provided are pharmaceutical formulations containing a therapeutically effective amount of one or more of the compounds, or... |
|
|
US20140315795 |
Compositions and Methods for Selective Delivery of Oligonucleotide Molecules to Cell Types
The invention provides a conjugate comprising (i) a nucleic acid which is complementary to a target nucleic acid sequence and which expression prevents or reduces expression of the target nucleic... |
|
|
US20140256620 |
METHODS FOR REDUCING CD36 EXPRESSION
The invention provides a method for treating one or more complications of diabetes in a mammal. The method comprises administering to a mammal in need thereof an effective amount of an... |
|
|
US20140213512 |
Method of Treating or Ameliorating Type 1 Diabetes Using FGF21
Methods of treating metabolic diseases and disorders using a FGF21 polypeptide are provided. In various embodiments the metabolic disease or disorder is type 1 diabetes, obesity, dyslipidemia,... |
|
|
US20130338063 |
Methods and Compositions for the Treatment of Gastrointestinal Disorders
Compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders,... |
|
|
US20130143796 |
CHIMERIC POLYPEPTIDES AND USES THEREOF
The disclosure provides nucleic acid molecules encoding chimeric polypeptides, chimeric polypeptides, pharmaceutical compositions comprising chimeric polypeptides, and methods for treating... |
|
|
US20070244048 |
Neuromedin U receptor agonists and uses thereof
Neuromedin U receptor agonists for use in the treatment of metabolic disorders such as obesity and diabetes are disclosed. |
|
|
US20070021346 |
N-terminally modified GLP-1 receptor modulators
The subject matter described herein provides novel human glucagon-like peptide-1 (GLP-1) receptor modulators that have biological activity similar or superior to native GLP-1 peptide and thus are... |
|
|
US20060188496 |
Intranasal administration of active agents to the central nervous system
A method for delivering a polypeptide to the central nervous system of a mammal is provided. The method involves attaching the polypeptide to an antibody or an antibody fragment and administering... |
|
|
US20150174266 |
APROTININ POLYPEPTIDES FOR TRANSPORTING A COMPOUND ACROSS THE BLOOD-BRAIN BARRIER
The invention relates to improvements in the field of drug delivery. More particularly, the invention relates to polypeptides derived from aprotinin and from aprotinin analogs as well as... |
|
|
US20140005096 |
METHODS OF TREATING INFLAMMATION
Disclosed herein, in certain embodiments, are peptides for use in inhibiting the interactions of PF4 and RANTES. Further disclosed herein, are methods for treating an inflammatory disease,... |
|
|
US20110105389 |
Macrocyclic Ghrelin Receptor Antagonists and Inverse Agonists and Methods of Using the Same
The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (GRLN, growth hormone... |
|
|
US20100317570 |
Composition and Method for the Treatment of Diseases Affected by a Peptide Receptor
The present invention includes peptidomimetic compound compositions and methods of making and using peptidomimetic compounds to modulate the activity of a peptide receptor for the treatment of one... |
|
|
US20070167374 |
Specific antagonists for glucose-dependent insulinotropic polypeptide (GIP)
In one embodiment, this invention provides an antagonist of glucose-dependent insulinotropic polypeptide (GIP) consisting essentially of a 24 amino acid polypeptide corresponding to positions 7-30... |
|
|
US20060121035 |
Methods for treating diabetes
Methods for treating diabetes by administering an inhibitor of GDF-8, or a related member of Transforming Growth Factor-beta (TGF-β) superfamily of structurally-related growth factors (e.g.,... |
|
|
US20050287180 |
Phospholipid compositions and methods for their preparation and use
The present invention provides compositions that comprise a phospholipid component (that contains one or more phospholipids) and a pharmaceutically acceptable fluid carrier, where the phospholipid... |
|
|
US20160175411 |
INFANT NUTRITION WITH PROTEASE INHIBITOR
Provided is an infant nutrition comprising at least one protease inhibitor, a process for preparing such an infant nutrition and use of the infant nutrition for the treatment and/or prevention of... |
|
|
US20160058874 |
CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY
Provided are methods relating to the use of CDP-therapeutic agent conjugates for the treatment of a disease or disorder, e.g., autoimmune disease, inflammatory disease, central nervous system... |
|
|
US20150094257 |
USE OF NUTRITIONAL COMPOSITIONS FOR PREVENTING DISORDERS
The present invention relates to a method for preventing and/or treating visceral adiposity and/or to alter body fat distribution by administering a certain nutritional composition to a human... |
|
|
US20140328794 |
ALBUMIN FUSION PROTEINS
The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors... |
|
|
US20140066368 |
Methods For Affecting Body Composition
Methods for affecting body composition include the use of amylin or amylin agonist(s). Total body weight be reduced, maintained or even increased; however, the body fat is reduced or body fat gain... |
|
|
US20120052069 |
FGF21 MUTANTS AND USES THEREOF
The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for... |
|
|
US20100129374 |
Mammalian Cell Membrane Proteins; Related Reagents
The purification and isolation of various genes which encode mammalian cell surface polypeptides. Nucleic acids, proteins, antibodies, and other reagents useful in modulating development of cells,... |
|
|
US20080299166 |
NOVEL BIOMATERIALS, THEIR PREPARATION AND USE
The present invention relates to novel materials, particularly biomaterials, in form of a precipitate, comprising at least an anionic polymeric component which is as such soluble in water and an... |
|
|
US20080176804 |
Methods for Affecting Body Composition
Methods for affecting body composition include the use of amylin or amylin agonist(s). Total body weight may be reduced, maintained or even increased; however, the body fat is reduced or body fat... |
|
|
US20070173455 |
Specific antagonists for glucose-dependent insulinotropic polypeptide (GIP)
In one embodiment, this invention provides an antagonist of glucose-dependent insulinotropic polypeptide (GIP) consisting essentially of a 24 amino acid polypeptide corresponding to positions 7-30... |
|
|
US20060154871 |
Peptides
The amino acid sequence of several peptides present in Colostrinin is disclosed. These peptides are useful, inter alia, in the treatment of disorders of the immune system and the central nervous... |
|
|
US20160220635 |
GLYCOPROTEINS HAVING LIPID MOBILIZING PROPERTIES AND THERAPEUTIC USES THEREOF
The invention provides compositions and methods for ameliorating symptoms associated with hyperglycemia by administering a Zn-α2-glycoprotein or a functional fragment thereof, methods of... |
|
|
US20140243259 |
GLYCOPROTEINS HAVING LIPID MOBILIZING PROPERTIES AND THERAPEUTIC USES THEREOF
The invention provides compositions and methods for ameliorating symptoms associated with hyperglycemia by administering a Zn-α2-glycoprotein or a functional fragment thereof, methods of... |
|
|
US20100113332 |
METHOD OF TREATING AN INFLAMMATORY DISEASE BY DOUBLE STRANDED RIBONUCLEIC ACID
What is disclosed is the use of a formulation comprising double stranded ribonucleic acid (dsRNA) in the manufacture of a medicament for treating an inflammatory disease in a mammal and inhibiting... |
|
|
US20090291886 |
TRANSMUCOSAL DELIVERY OF PEPTIDES AND PROTEINS
Provided are methods and compositions for enhancing the transmucosal absorption of bioactive peptides and proteins. More particularly, the invention provides compositions for enhancing the... |
|
|
US20090028814 |
HIGH MOLECULAR WEIGHT MEDICINE-CONTAINING PREPARATION IN POWDER FORM FOR ADMINISTRATION THROUGH MUCOSA
A preparation in powder form for administration through mucosa, comprising a medicine of high molecular weight and a cationic polymer is disclosed. By adding a cationic polymer (in particular, a... |
|
|
US20090011995 |
PRODUCTION OF A SOLUBLE NATIVE FORM OF RECOMBINANT PROTEIN BY THE SIGNAL SEQUENCE AND SECRETIONAL ENHANCER
The present invention is drawn to a method for enhancing secretional efficiency of a heterologous protein using a secretional enhancer consisting of a modified signal sequence which comprises the... |
|
|
US20070054851 |
Methods of and compositions for stimulation of glucose uptake into muscle cells and treatment of diseases
The present invention relates to therapeutic uses of ErbB ligands, including betacellulin. The therapeutic uses include methods of using ErbB ligand family compounds alone, or in conjunction with... |
|
|
US20070010450 |
Methods and compositions for the treatment of gastrointestinal disorders
Compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders,... |